scholarly journals Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents

2022 ◽  
Vol 13 (1) ◽  
Author(s):  
Nina Koerber ◽  
Alina Priller ◽  
Sarah Yazici ◽  
Tanja Bauer ◽  
Cho-Chin Cheng ◽  
...  
Keyword(s):  
T Cells ◽  
Neutralizing Antibody ◽  
Simultaneous Increase ◽  
Delayed Response ◽  
Viral Immunity ◽  
Specific Immunity ◽  
Long Term Follow Up ◽  
Antibody Titers

AbstractAnti-viral immunity continuously declines over time after SARS-CoV-2 infection. Here, we characterize the dynamics of anti-viral immunity during long-term follow-up and after BNT162b2 mRNA-vaccination in convalescents after asymptomatic or mild SARS-CoV-2 infection. Virus-specific and virus-neutralizing antibody titers rapidly declined in convalescents over 9 months after infection, whereas virus-specific cytokine-producing polyfunctional T cells persisted, among which IL-2-producing T cells correlated with virus-neutralizing antibody titers. Among convalescents, 5% of individuals failed to mount long-lasting immunity after infection and showed a delayed response to vaccination compared to 1% of naïve vaccinees, but successfully responded to prime/boost vaccination. During the follow-up period, 8% of convalescents showed a selective increase in virus-neutralizing antibody titers without accompanying increased frequencies of circulating SARS-CoV-2-specific T cells. The same convalescents, however, responded to vaccination with simultaneous increase in antibody and T cell immunity revealing the strength of mRNA-vaccination to increase virus-specific immunity in convalescents.

scholarly journals Comparative quantitative analysis of SARS-CoV-2 Spike neutralizing antibody titers following two anti COVID-19 vaccines in India

2021 ◽  
Author(s):  
Chanukya GV ◽  
Aparna Srikantam
Keyword(s):  
Quantitative Analysis ◽  
Neutralizing Antibodies ◽  
Large Scale ◽  
Neutralizing Antibody ◽  
Long Term Follow Up ◽  
Antibody Titers ◽  
Age Studies ◽  
Immunogenic Response

In COVID 19 pandemic, first line of defense is effective vaccination program. Because of multiple platforms available for vaccine production we tested relative immunogenicity of two vaccines available in India, Covaxin and Covishield We performed quantitative analysis of neutralizing antibodies to SARS Cov2 spike (receptor binding domain ) protein, from sera of 53 subjects who completed vaccines schedules. There was significantly higher immunogenic response with Covishield as compared to Covaxin and are independent of age. Studies on a large scale with long term follow up are needed to further advance the knowledge in this domain.

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells

10.1038/nm880 ◽  
2003 ◽  
Vol 9 (6) ◽  
pp. 727-728 ◽  
Author(s):  
Janet D Siliciano ◽  
Joleen Kajdas ◽  
Diana Finzi ◽  
Thomas C Quinn ◽  
Karen Chadwick ◽  
...  
Keyword(s):  
T Cells ◽  
Cd4 T Cells ◽  
Latent Reservoir ◽  
Follow Up Studies ◽  
Long Term Follow Up ◽  
The Stability ◽  
Hiv 1

Reconstitution of the T Cell Repertoire Following Treatment with Alemtuzumab in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 2986-2986
Author(s):  
Mohammad R. Rezvany ◽  
Mahmood J. Tehrani ◽  
Claes Karlsson ◽  
Jeanette Lundin ◽  
Hodjattallah Rabbani ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
B Cell ◽  
Cd8 T Cells ◽  
Cd4 T Cells ◽  
T Cell Repertoire ◽  
Cell Repertoire ◽  
Long Term Follow Up

Abstract Background and Methods: B-cell chronic lymphocytic leukemia (B-CLL) occurs as a result of clonal accumulation of functionally abnormal B cells. Alemtuzumab is a humanized monoclonal antibody specific for the CD52 antigen, which is highly expressed on both B-CLL cells and normal lymphocytes, but not on hematopoietic (CD34) stem cells. Alemtuzumab has been shown to effectively deplete the blood and bone marrow of lymphocytes, including CD4 and CD8 T cells, which may lead to profound immunosuppression and make patients more susceptible to infections. We and others have previously shown that the CD4 T cells in B-CLL patients may be clonally distinct from the normal population in that they present a more clonal pattern of the T-cell receptor (TCR) repertoire (Rezvany et al, Blood2003;101:1063–1070). It is therefore of interest to study the T cell repertoire following alemtuzumab administration as well as factors affecting T cell reconstitution following CD52 targeted therapy. In this study, we evaluated in depth the T-cell receptor-beta-variable sequence (TCR BV) in CD4 and CD8 T cells by real-time PCR, before and repeatedly after/during long term follow-up, in 5 B-CLL patients who had received alemtuzumab as first-line therapy (Lundin et al, Blood2002;100:768–773). Also, an analysis was conducted of CDR3 length polymorphism to describe changes in the clonality pattern. Results: A decline in most of BV genes either in CD4 or CD8 T cells was observed shortly after alemtuzumab treatment, which was followed by a gradual increase in most of the BV genes during long-term follow up. CDR3 length polymorphism analysis shortly after treatment revealed an even more highly restricted pattern in CD4 T cells compared to baseline with a shift towards a monoclonal/oligoclonal pattern regardless of increased or decreased BV usage. Furthermore, in the analysis of the clonal spectrum that was expressed shortly after alemtuzumab therapy, the number of peaks was significantly reduced in CD4 (P <0.01) but not in CD8 T cells, which was followed by a gradual increase in diversity towards a polyclonal repertoire during long-term follow up. Conclusions: These results indicate that perturbations in the T cell repertoire following alemtuzumab are complex, and are not reflected by changes in CD4/CD8 T cell numbers only. The restricted CDR3 pattern present prior to therapy became even more restricted after end of treatment, followed by a normalization of CDR3 patterns in CD4 T-cells during long-term follow-up. These results further suggest a regulatory role for T cells in relation to the malignant B cell clone in patients with B-CLL.

An AS04-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15–55 years old

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 1008-1008 ◽  
Author(s):  
T. F. Schwarz
Keyword(s):  
Sexual Debut ◽  
Geometric Mean ◽  
Phase Iii ◽  
Cervical Lesions ◽  
Hpv 16 ◽  
Long Term Follow Up ◽  
Antibody Titers ◽  
Antibody Levels

1008 Background: Genital HPV infections can be acquired shortly after sexual debut, and the risk remains throughout a sexually active woman’s lifetime. In women 15–25 years of age, the AS04-containing HPV vaccine was highly immunogenic and conferred 100% protection against HPV-16/18 persistent infection and associated cervical lesions up to 27 months. In the long-term follow-up of this study, sustained vaccine efficacy has been observed up to 48 months. The present phase III study (580299/014) assessed immune responses to the AS04-containing HPV-16/18 vaccine in women 26–55 years old compared with women 15–25 years old. Methods: Healthy women in Germany and Poland between 15 and 55 years of age received 3 doses of HPV-16/18 AS04-containing vaccine at months 0, 1, and 6. The groups were age stratified: 15–25 (n=229), 26–45 (n=226), and 46–55 (n=211). Anti-HPV-16/18 antibody titers were assessed at months 0, 2, 7, and 12 by ELISA (EU/mL). Seropositivity rates and geometric mean antibody titers (GMTs) were calculated for all groups. Safety was assessed after each dose in all participants. Results: All initially seronegative women became seropositive for both HPV 16 and 18 at Month 2. At Month 7, HPV-16 GMTs (95% CI) were 7908.4 (6874.0–9098.5) in 15–25 year olds, 4029.2 (3402.7–4771.0) in 26–45 year olds, and 2566.8 (2181.2–3020.6) in 46–55 year olds. For HPV-18, GMTs were 3499.3 (3098.7–3951.6) in 15–25 year olds, 1837.3 (1602.1–2107.0) in 26–45 year olds, and 1313.0 (1145.6–1504.9) in 46–55 year olds. Overall the vaccine was well-tolerated, and the incidence of local symptoms (within 30 days) tended to be lower in the 46–55 year-old group (69.2% versus 81.6% [26–45] and 85.7% [15–25]). Conclusions: An AS04-containing HPV-16/18 vaccine was immunogenic and generally safe in 15–55 year-old females. As observed with other vaccines, GMTs decreased with age, however, the Month 7 postvaccination antibody levels in the oldest age group (46–55) were still 3–4 times higher than those observed during a separate long-term follow-up study where sustained efficacy has been observed up to 48 months. [Table: see text]

Long-term follow up for a phase I trial HER2/neu-targeted T cells in women with advanced breast cancer.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 3075-3075
Author(s):  
Lawrence G. Lum ◽  
Archana Thakur ◽  
Zaid S. Al-Kadhimi ◽  
Gerald A. Colvin ◽  
Francis J. Cummings ◽  
...  
Keyword(s):  
Breast Cancer ◽  
T Cells ◽  
Phase I ◽  
Advanced Breast Cancer ◽  
Phase I Trial ◽  
Advanced Breast ◽  
Long Term Follow Up

scholarly journals Long-term SARS-CoV-2 RNA Shedding and its Temporal Association to IgG Seropositivity

2020 ◽  
Author(s):  
Vineet Agarwal ◽  
AJ Venkatakrishnan ◽  
Arjun Puranik ◽  
Christian Kirkup ◽  
Agustin Lopez-Marquez ◽  
...  
Keyword(s):  
Upper Bound ◽  
Neutralizing Antibody ◽  
Initial Diagnosis ◽  
Viral Rna ◽  
Temporal Association ◽  
Viral Loads ◽  
Antibody Titers ◽  
The Mean

Analysis of 851 COVID-19 patients with a SARS-CoV-2-positive PCR at follow-up shows 99 patients remained SARS-CoV-2-positive after four weeks from initial diagnosis. Surprisingly, a majority of these long-term viral RNA shedders were not hospitalized (61 of 99), with variable PCR Crossing point values over the month post diagnosis. For the 851-patient cohort, the mean lower bound of viral RNA shedding was 17.3 days (SD: 7.8), and the mean upper bound of viral RNA shedding from 668 patients transitioning to confirmed PCR-negative status was 22.7 days (SD: 11.8). Among 104 patients with an IgG test result, 90 patients were seropositive to date, with mean upper bound of time to seropositivity from initial diagnosis being 37.8 days (95%CI: 34.3-41.3). Juxtaposing IgG/PCR tests revealed that 14 of 90 patients are non-hospitalized and seropositive yet shed viral RNA. This study emphasizes the need for monitoring viral loads and neutralizing antibody titers in long-term shedders.

scholarly journals Long COVID in a prospective cohort of home-isolated patients

2021 ◽  
Author(s):  
Bjørn Blomberg ◽  
Kristin Greve-Isdahl Mohn ◽  
Karl Albert Brokstad ◽  
Fan Zhou ◽  
Dagrun Waag Linchausen ◽  
...  
Keyword(s):  
Prospective Cohort ◽  
Control Measures ◽  
Persistent Symptoms ◽  
Infection Control Measures ◽  
Memory Problems ◽  
Long Term Follow Up ◽  
Antibody Titers ◽  
Pandemic Wave

AbstractLong-term complications after coronavirus disease 2019 (COVID-19) are common in hospitalized patients, but the spectrum of symptoms in milder cases needs further investigation. We conducted a long-term follow-up in a prospective cohort study of 312 patients—247 home-isolated and 65 hospitalized—comprising 82% of total cases in Bergen during the first pandemic wave in Norway. At 6 months, 61% (189/312) of all patients had persistent symptoms, which were independently associated with severity of initial illness, increased convalescent antibody titers and pre-existing chronic lung disease. We found that 52% (32/61) of home-isolated young adults, aged 16–30 years, had symptoms at 6 months, including loss of taste and/or smell (28%, 17/61), fatigue (21%, 13/61), dyspnea (13%, 8/61), impaired concentration (13%, 8/61) and memory problems (11%, 7/61). Our findings that young, home-isolated adults with mild COVID-19 are at risk of long-lasting dyspnea and cognitive symptoms highlight the importance of infection control measures, such as vaccination.

Sign in / Sign up

Export Citation Format

Share Document